Materials and Methods

Paterson PY , Swanborg RH. (1988) Demyelinating diseases of the central and peripheral nervous systems. In: M. Samter et al. (ed.). Immunological Diseases, 4th edition. Little, Brown and Company: Boston/Toronto pp 1877-1916.

Martin R , McFarland HF , McFarlin DE. (1992) Immunological aspects of demyelinating diseases . Annu Rev Immunol 10: 153-157 .

Issazadeh S et al. (1995) Interferon γ, interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in Lewis rats: Dynamics of cellular mRNA expression in the central nervous system and lymphoid cells . J Neurosci Res 40: 579-590 .

Linsley PS , Ledbetter JA. (1993) The role of the CD28 receptor during T cell responses to antigen . Annu Rev Immunol 11: 191-212 .

Jenkins MK. (1994) The ups and downs of costimulation . Immunity 1: 443-446 .

June CH et al. (1994) The B7 and CD28 receptor families . Immunol. Today 15: 321-331 .

Teitelbaum D et al. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide . Eur J Immunol 1: 242-248 .

Teitelbaum D et al. (1973) Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen . Eur J Immunol 3: 273-279 .

Yu M et al. (1996) Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis . J Neuroimmunol 64: 91-100 .

Paty DW , Li DK. (1993) Interferon beta-1β is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN? Multiple Sclerosis Study Group . Neurology 43: 662-667 .

Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology 45: 1268-1276 .

Hohlfeld R. (1997) Biotechnical agents for the immunotherapy of mutiple sclerosis . Brain 120: 865-916 .

Higgins PJ , Weiner HL. (1988) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments . J Immunol 140: 440-445 .

Whitacre CC et al. (1991) Oral tolerance in experimental autoimmune encephalomyelitis III: Evidence for clonal anergy . J Immunol 147: 2155-2163 .

Al-Sabbagh A , Miller A , Weiner HL. (1993) Suppression of EAE by oral and intravenous myelin basic protein, and by T-cell receptor peptide prior to or following disease expression . Neurol 43: A411-A411 .

Levine S , Hoenig EM , Kies MW. (1968) Allergic encephalomyelitis: Passive transfer prevented by encephalitogen . Science 161: 1155-1157 .

Levine S , Hoenig EM , Kies MW. (1970) Allergic encephalomyelitis: Immunologically specific inhibition of cellular passive transfer by encephalitogenic basic proteins . Clin Exp Immunol 6: 503-517 .

Karin N et al. (1994) Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor a production . J Exp Med 180: 2227-2237 .

Gaur A et al. (1992) Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy . Science 258: 1491-1494 .

Harling-Berg CJ , Knopf PM , Cserr HF. (1991) Myelin basic protein infused into cerobrospinal fluid suppresses experimental autoimmune encephalomyelitis . J Neuroimmunol 35: 45-51 .

Swierkosz JE , Swanborg RH. (1975) Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis . J Immunol 115: 631-633 .

Swierkosz JE , Swanborg RH. (1977) Immunoregulation of experimental allergic encephalomyelitis: Conditions for induction of suppressor cells and analysis of mechanism . J Immunol 119: 1501-1506 .

Marusic S , Tonegawa S. (1997) Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide . J Exp Med 186: 507-515 .

Miller SD et al. (1992) Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis Intern Rev Immunol 9: 203-222 .

Pope L , Paterson PY , Miller SD. (1992) Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats . J Neuroimmunol 37: 177-190 .

Tan L-J et al. (1991) Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance . J Immunol 147: 1797-1802 .

Kennedy MK et al. (1988) Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice . J Immunol 141: 2986-2993 .

Miller A , Hafler DA , Weiner HL. (1991) Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: Implications for immunotherapy of human autoimmune diseases . FASEB 5: 2560-2566 .

Van Parijs L , Abbas AK. (1998) Homeostasis and selftolerance in the immune system: turning off lymphocytes off . Science 280: 243-248 .

Freidman A , Weiner HL. (1994) Induction of anergy or active suppression following oral tolerance is determined by antigen dosage . Proc Natl Acad Sci 91: 6688-6692 .

Warren KG , Catz I. (1995) Administration of myelin basic protein synthetic peptides to multiple sclerosis patients . J Neurol Sci 133: 85-94 .

Warren KG , Catz I. (1997) The effect of intrathecal MBP synthetic peptides containing epitope P85VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis . J Neurol Sci 148: 67-78 .

Deibler DE , Martenson RE , Keyes MW. (1972) Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species . Prep Biochem 2: 139-165 .

Chou C-H et al. (1977) The major site of guinea-pig myelin basic protein encephalitogenic in Lewis rats . J Neurochem 28: 115-119 .

Chen Y et al. (1994) Regulatory T cells induced by oral tolerance: Suppression of Autoimmune encephalomyelitis . Science 265: 1237-1240 .

Lider O et al. (1989) Suppression of experimental allergic encephalomyelitis by oral administration of myelin basic protein II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes . J Immunol 142: 748-752 .

Miller A , Lider O , Weiner HL. (1991) Antigen-driven bystander suppression after oral administration of antigens . J Exp Med 174: 791-798 .

Kearney ER et al. (1995) Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivi is dependent on CD28 costimulation and inhibited by CTLA-4 . J Immunol 155: 1032-1036 .

Jenkins MK , Schwartz RH. (1987) Antigen presentation by chemically modified splenocytes induces antigenspecific T cell unresponsiveness in vitro and in vivo . J Exp Med 165: 302-319 .

Critchfield JM et al. (1994) T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis . Science 263: 1139-1143 .

Racke MK et al. (1996) Intravenous antigen administration as a therapy for autoimmune demyelinating disease . Annal Neurol 39: 46-56 .

Kabelitz D , Pohl T , Pechhold K. (1993) Activation induced cell death (apoptosis) of mature peripheral T lymphocytes . Immunology Today 14: 338-339 .

Lenardo M. (1991) Interleukin-2 programs mouse αβ T lymphocytes for apoptosis . Nature 353: 858-861 .